Organovo Holdings Company Profile (AMEX:ONVO)

About Organovo Holdings (AMEX:ONVO)

Organovo Holdings logoOrganovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: AMEX:ONVO
  • CUSIP: N/A
  • Web: organovo.com/
Average Prices:
  • 50 Day Moving Avg: $2.04
  • 200 Day Moving Avg: $2.47
  • 52 Week Range: $1.46 - $4.08
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.35
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $4.33 million
  • Price / Sales: N/A
  • Book Value: $0.54 per share
  • Price / Book: 2.74
Profitability:
  • EBITDA: ($38,770,000.00)
  • Net Margins: -1,020.40%
  • Return on Equity: -67.74%
  • Return on Assets: -61.91%
Misc:
  • Average Volume: 1.05 million shs.
  • Short Ratio: 21.68
 

Frequently Asked Questions for Organovo Holdings (AMEX:ONVO)

What is Organovo Holdings' stock symbol?

Organovo Holdings trades on the AMEX under the ticker symbol "ONVO."

Where is Organovo Holdings' stock going? Where will Organovo Holdings' stock price be in 2017?

2 analysts have issued 12 month price targets for Organovo Holdings' shares. Their forecasts range from $3.75 to $3.75. On average, they expect Organovo Holdings' share price to reach $3.75 in the next twelve months. View Analyst Ratings for Organovo Holdings.

Who are some of Organovo Holdings' key competitors?

Who are Organovo Holdings' key executives?

Organovo Holdings' management team includes the folowing people:

  • Taylor J. Crouch, President, Chief Executive Officer
  • Eric Michael David M.D. J.D., Executive Vice President - Pre-Clinical Development, Chief Strategy Officer
  • Sharon Collins Presnell Ph.D., Chief Scientific Officer
  • Jennifer Kinsbruner Bush J.D., Compliance Officer, General Counsel, Corporate Secretary
  • Paul Gallant, General Manager
  • Richard Maroun, Director
  • Robert F. Baltera Jr., Lead Independent Director
  • James T. Glover, Independent Director
  • Richard A. Heyman Ph.D., Independent Director
  • Tamar D. Howson, Independent Director

How do I buy Organovo Holdings stock?

Shares of Organovo Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Organovo Holdings' stock price today?

One share of Organovo Holdings stock can currently be purchased for approximately $1.48.


MarketBeat Community Rating for Organovo Holdings (AMEX ONVO)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  41 (Vote Outperform)
Underperform Votes:  37 (Vote Underperform)
Total Votes:  78
MarketBeat's community ratings are surveys of what our community members think about Organovo Holdings and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Organovo Holdings (AMEX:ONVO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.75
Consensus Price Target History for Organovo Holdings (AMEX:ONVO)
Price Target History for Organovo Holdings (AMEX:ONVO)
Analysts' Ratings History for Organovo Holdings (AMEX:ONVO)
Show:
DateFirmActionRatingPrice TargetDetails
6/12/2017Evercore ISILower Price TargetOutperform$4.00 -> $3.75View Rating Details
1/25/2017Raymond James Financial, Inc.Initiated CoverageOutperformView Rating Details
(Data available from 10/18/2015 forward)

Earnings

Earnings History for Organovo Holdings (AMEX:ONVO)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Organovo Holdings (AMEX:ONVO)
Current Year EPS Consensus Estimate: $-0.39 EPS
Next Year EPS Consensus Estimate: $-0.34 EPS

Dividends

Dividend History for Organovo Holdings (AMEX:ONVO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Organovo Holdings (AMEX:ONVO)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Organovo Holdings (AMEX:ONVO)
Latest Headlines for Organovo Holdings (AMEX:ONVO)
Source:
DateHeadline
finance.yahoo.com logoWhen Will Organovo Holdings Inc (ONVO) Come Back To Market?
finance.yahoo.com - October 5 at 11:58 PM
fool.com logoHere's Why Organovo Holdings Inc Fell 10.5% in June
www.fool.com - July 10 at 11:29 AM
thestreet.com logoEQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Intra-Cellular Therapies, Inc. - ITCI
www.thestreet.com - May 13 at 12:47 AM
fool.com logoWhy Organovo Holdings Inc Shareholders Have Something to Worry About
www.fool.com - April 18 at 5:48 PM
reuters.com logoBRIEF-Organovo reports CEO transition
www.reuters.com - April 11 at 6:55 PM
fool.com logoWhat's Next for Organovo Holdings Inc.?
www.fool.com - April 11 at 7:30 AM
streetinsider.com logoOrganovo (ONVO) Publishes Data Describing Physiology of 3D Bioprinted Human Kidney Tissues for Drug Toxicity Testing
www.streetinsider.com - February 21 at 5:50 PM
fool.com logoOrganovo Holdings' Unpleasant Q3 Surprise: Still Plenty of Skepticism About 3D Tissues
www.fool.com - February 10 at 1:10 AM
biz.yahoo.com logoOrganovo Holdings Inc Earnings Call (Q3 2017)
biz.yahoo.com - February 9 at 1:01 AM
fool.com logoThe Possible Reason Behind Organovo Holdings, Inc.'s Big Climb in April
www.fool.com - May 5 at 10:38 AM
fool.com logo3 Ways Technology Is Set to Change the Face of Healthcare
www.fool.com - March 19 at 9:04 AM
streetinsider.com logoOrganovo (ONVO) Announces Presentations of exVive3DTM Human Liver Model Data at SOT Annual Meeting
www.streetinsider.com - March 10 at 11:49 AM
fool.com logo5 Key Takeaways from Organovo Holdings Inc.'s Investor Conference
www.fool.com - February 12 at 2:42 PM
biz.yahoo.com logoORGANOVO HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - February 8 at 4:09 PM
fool.com logoWhat's Going on With Organovo Holdings, Inc.?
www.fool.com - January 22 at 8:40 AM
biz.yahoo.com logoORGANOVO HOLDINGS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib
biz.yahoo.com - January 19 at 8:06 AM

Social

Social activity is not available for this stock.

Chart

Organovo Holdings (ONVO) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.